Scholarlink

<p>Advanced cholangiocarcinoma is associated with a&#xa0;poor prognosis despite standard platinum-based chemotherapy. Recently, the addition of immune checkpoint inhibitors has provided a&#xa0;modest survival benefit. Approximately half of patients harbor somatic molecular alterations that are potentially actionable with targeted therapies. Early molecular profiling of tumor tissue is therefore essential to guide treatment decisions. Future strategies aim to expand therapeutic options through novel immunotherapies, emerging molecular targets and sequential treatment approaches designed to overcome resistance mutations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Targeted therapies in advanced cholangiocarcinoma: new targets and strategies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月18日

查看全文
  • Hannes Windhager,
  • Bernhard Doleschal

摘要

Advanced cholangiocarcinoma is associated with a poor prognosis despite standard platinum-based chemotherapy. Recently, the addition of immune checkpoint inhibitors has provided a modest survival benefit. Approximately half of patients harbor somatic molecular alterations that are potentially actionable with targeted therapies. Early molecular profiling of tumor tissue is therefore essential to guide treatment decisions. Future strategies aim to expand therapeutic options through novel immunotherapies, emerging molecular targets and sequential treatment approaches designed to overcome resistance mutations.